Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on equity-38.7%
Return on assets-32.6%+8.6pp-41.1%
Return on invested capital-117.8%
Liquidity
Current ratio17.9×+2.4×15.5×-2.2×17.7×+4.1×13.6×-2.5×16.1×+6.3×
Quick ratio17.9×+2.4×15.5×-2.2×17.7×+4.1×13.6×-2.5×16.1×+6.3×
Cash ratio9.4×+1.0×8.4×-5.9×14.3×+1.0×13.3×-2.5×15.8×+6.3×
Leverage
Debt-to-equity0.2×+0.1×0.1×0.0×0.1×0.0×0.1×0.0×0.1×
Debt-to-assets0.1×+0.1×0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×
Per Share
Book value per share$6.34-23.2%$8.26-0.3%$8.29+38.4%$5.99-41.3%$10.20+109%
Valuation
Market capitalization$1.48B+201%$1.99B+75.3%$1.14B+151%$452.42M
Enterprise value$1.34B$1.83B+116%$844.46M+297%$212.89M
Price / book4.3×5.6×+2.6×+1.3×1.7×
Free cash flow yield-8.3%-5.7%
Earnings yield-8.3%-6.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Maze Therapeutics, Inc. Common Stock's ratios come from?
Every ratio is computed from Maze Therapeutics, Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.